Maravai LifeSciences Holdings, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Maravai LifeSciences Holdings, Inc. | MRVI - NASDAQ |
$24.00-$27.00 | $27.00 | $31.95 | 60 million | 11/20/2020 |
| Morgan Stanley, Jefferies, Goldman Sachs, BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, KeyBanc Capital | ||||||
Co-Manager(s): Academy Securities, Loop Capital, Penserra Securities, Tigress Financial Partners | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-29 Terms Added 2020-11-13 | ||||||
Maravai LifeSciences Holdings, Inc. Quote & Chart - Click for current quote - MRVI
IPO Boutique aggregates information on public companies and private companies, such as "MRVI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Maravai LifeSciences Holdings, Inc. (adapted from Maravai LifeSciences Holdings, Inc. prospectus):
They are a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MRVI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.